Paratek Pharmaceuticals, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Net revenue
Product revenue, net
Government contract service revenue
Government contract grant revenue
Collaboration and royalty revenue
Total net revenue
Expenses:
Cost of product revenue
Research and development
General and administrative
Selling, general and administrative
Impairment of intangible assets
Changes in fair value of contingent consideration
Total operating expenses

Loss from operations
Other income and expenses:
Interest income
Interest expense
Loss on extinguishment of debt
Other gains (losses), net
Net loss before provision for income taxes
Provision for income taxes
Net loss
Other comprehensive loss
Unrealized gain (loss) on available-for-sale securities, net of tax
Other comprehensive gain (loss)
Comprehensive loss
Basic and diluted net loss per common share
Weighted average common shares outstanding Basic and diluted
Earnings per share, diluted (in USD per share)
Earnings per share, basic (in USD per share)
Weighted average common shares outstanding
Weighted average number of shares outstanding, diluted
Weighted average number of shares outstanding, basic

Comments